Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

Letters   |    
Tardive dyskinesia in a pregnant woman with low dose, short-duration risperidone: possible role of estrogen-induced dopaminergic hypersensitivity
Biswadip Chatterjee, M.D.; Pratap Sharan, M.D., Ph.D.
The Journal of Neuropsychiatry and Clinical Neurosciences 2014;26:E44-E46. doi:10.1176/appi.neuropsych.13030049
View Author and Article Information

Disclosure of interest: None to declare.

Source of funding: None to declare.

Dept. of Psychiatry,
All India Institute of Medical Sciences
New Delhi, 110029, India

Correspondence: Dr. Chatterjee; e-mail: biswadip.c@gmail.com

Copyright © 2014 American Psychiatric Association


To the Editor: The second-generation antipsychotics (SGAs), as compared with first-generation antipsychotics (FGAs), are considered to have lower risk of movement disorders as side effect. We report a case of a 34-year-old woman with bipolar disorder-I who developed orofacial dyskinetic movements with short exposure to a low dose of risperidone during pregnancy that continued to exacerbate despite stopping the medication. We discuss the possible role of pregnancy in sensitizing this side effect.

Figures in this Article

First Page Preview

View Large
First page PDF preview
Your Session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).



Correll  CU;  Leucht  S;  Kane  JM:  Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.  Am J Psychiatry 2004; 161:414–425
[CrossRef] | [PubMed]
Miller  DD;  Caroff  SN;  Davis  SM  et al: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators:  Extrapyramidal side-effects of antipsychotics in a randomised trial.  Br J Psychiatry 2008; 193:279–288
[CrossRef] | [PubMed]
Chan  H-Y;  Chiang  S-C;  Chang  C-J  et al:  A randomized, controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia.  J Clin Psychiatry 2010; 71:1226–1233
[CrossRef] | [PubMed]
Keck  PE  Jr;  McElroy  SL;  Strakowski  SM  et al:  Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia.  J Clin Psychiatry 2000; 61(Suppl 4):33–38
[CrossRef] | [PubMed]
Egan  MF;  Apud  J;  Wyatt  RJ:  Treatment of tardive dyskinesia.  Schizophr Bull 1997; 23:583–609
[CrossRef] | [PubMed]
Dinan  TG;  Kohen  D:  Tardive dyskinesia in bipolar affective disorder: relationship to lithium therapy.  Br J Psychiatry 1989; 155:55–57
[CrossRef] | [PubMed]
Schooler  NR;  Kane  JM:  Research diagnoses for tardive dyskinesia.  Arch Gen Psychiatry 1982; 39:486–487
Munetz  MR;  Benjamin  S:  How to examine patients, using the Abnormal Involuntary Movement Scale.  Hosp Community Psychiatry 1988; 39:1172–1177
Suzuki  E;  Obata  M;  Yoshida  Y  et al:  Tardive dyskinesia with risperidone and anticholinergics.  Am J Psychiatry 2002; 159:1948
[CrossRef] | [PubMed]
Mendhekar  DN;  Gupta  D;  Mehndiratta  MM:  Risperidone-induced tardive movements in young adult patients.  Indian J Pharmacol 2004; 36:183
Bassitt  DP;  de Souza Lobo Garcia  L:  Risperidone-induced tardive dyskinesia.  Pharmacopsychiatry 2000; 33:155–156
[CrossRef] | [PubMed]
Sánchez  MG;  Bourque  M;  Morissette  M  et al:  Steroids–dopamine interactions in the pathophysiology and treatment of CNS disorders.  CNS Neurosci Ther 2010; 16:e43–e71
[CrossRef] | [PubMed]
Gordon  JH;  Borison  RL;  Diamond  BI:  Estrogen in experimental tardive dyskinesia.  Neurology 1980; 30:551–554
[CrossRef] | [PubMed]
References Container

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe

Related Content
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 26.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 20.  >
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 27.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 9.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 20.  >
Topic Collections
Psychiatric News
Read more at Psychiatric News >>
PubMed Articles